You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Drug Funding Options for Glomerulonephritis

Many people with glomerulonephritis (GN) require immunosuppressant therapy to help manage the condition. These drugs may be funded by government drug programs, private insurance or manufacturer-supported programs, or paid for directly by the patient. We provide information, plus relevant links and forms, for each of these options.

Overview of drug funding options

Funding Option


Private Insurance

For people who have purchased private insurance or have private insurance coverage through their employer.

  • Plans vary depending on different insurance companies and individual plans.
  • Patients should contact their plan with the drug identification number (DIN) for the required medications to enquire about coverage (see Private Insurance to find DIN numbers).

Ontario Drug Benefit (ODB) & OHIP+

For Ontario Residents with Ontario Health Insurance Plan (OHIP) who meet one of these criteria:

  • Age 24 years and under
  • Seniors over 65 years old
  • Living in a long-term care home or a home for special care
  • Enrolled in one of these programs:
    • Home care
    • Ontario Works
    • Ontario Disability Support Program (ODSP)

Trillium Drug Program (TDP)

Ontario Residents with OHIP, regardless of their income, may apply if they do not have private insurance or their private insurance does not cover 100% of their prescription drug costs.

  • Covers same medications as ODB.

Federal Non-Insured Health Benefits (NIHB) Program

Registered First Nations and recognized Inuit people may be eligible for the NIHB. For eligibility details, visit Who is eligible for the Non-Insured Health Benefits Program.

Interim Federal Health Program (IFHP)

People in the following groups who are not eligible for provincial health insurance may be eligible for the IFHP:

  • Protected persons, including resettled refugees
  • Refugee claimants
  • Certain other groups

No Medication Coverage

  • Patient can enroll into TDP, manufacturer-supported programs or pay cash.

Disclaimer: The information contained herein (“Information”) is intended for informational purposes only, and no warranty as to its accuracy is provided or implied. The Information was collected from third party sources and is subject to change without notice. Cancer Care Ontario (CCO) makes no warranty that the Information is current. The Information is intended for use by healthcare professionals to advise patients of drug funding options that may be available to them. Do not act or rely upon the Information without exercising your independent judgment or seeking the advice of a qualified professional. Anyone using the Information does so at his or her own risk. The drug funding options described on this website are managed and funded by third parties, not by CCO. Please direct any inquiries to the applicable agency/entity who manages the drug funding option.